Open an account

BioRestorative Therapies

BRTX · NASDAQ

$1.56−$0.04 (−2.50%)TodayMarket closed ·
Prev close $1.60

About BRTX

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. The company is headquartered in Melville, New York and currently employs 13 full-time employees. The company went IPO on 2001-07-11. The firm has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The company has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The firm is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. The company also operates a commercial biocosmeceutical platform.

Employees
14
Headquarters
Melville, New York
Listed
Jul 11, 2001
Sector
Health Care
Industry
Biotechnology
Website
biorestorative.com

BRTX key statistics

Market cap
2.15M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
38.16K
Volume
16.52K
Open price
$1.59
High today
$1.65
Low today
$1.54
52 Week high
$34.40
52 Week low
$1.28

BioRestorative Therapies (BRTX) at a glance

As of Oct 20, 2026, BioRestorative Therapies (BRTX) shares are priced at $1.56, giving the company a market cap of 2.15M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.54 and $1.65. The current price is 1.3% above the day's low and 5.5% below its high.

Volume so far is 16.52K shares, below the average of 38.16K shares a day.

Over the past year BioRestorative Therapies has ranged from $1.28 to $34.40, and now sits 1% of the way up that range.

BioRestorative Therapies met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q1 FY26 it reported -$2.40 per share against an estimate of -$4.08.

The average analyst price target is $163.20, 10361.5% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 4 analystsAvg $163.20
Low
$20.20
Now
$1.56
High
$315.00

BRTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 28.9% on average.

  1. Q2 FY24: reported -$0.50 per share against an estimate of -$0.5712
  2. Q3 FY24: reported -$0.134 per share against an estimate of -$0.4386
  3. Q4 FY24: reported -$0.20 per share against an estimate of -$0.2805
  4. Q1 FY25: reported -$0.64 per share against an estimate of -$0.3315
  5. Q2 FY25: reported -$0.30 per share against an estimate of -$0.3876
  6. Q3 FY25: reported -$0.33 per share against an estimate of -$0.3672
  7. Q4 FY25: reported -$6.20 per share against an estimate of -$7.55
  8. Q1 FY26: reported -$2.40 per share against an estimate of -$4.08

BRTX news

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Avi Kapoor

    Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results

  • Press releasePRNewswire

    Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

Similar companies

Companies in the same industry as BioRestorative Therapies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.